PROKIDNEY CORP (PROK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.01+4.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PROK
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 0.8 | 0.9 | 0.1 | 0.0 | 0.0 | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 130.9 | 114.1 | 127.7 | 106.7 | 82.1 | 46.3 | 21.0 |
| Operating Income | (177.2) | (165.0) | (183.7) | (151.5) | (153.0) | (55.1) | (27.0) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 |
| Interest & Investment Income | 10.5 | 13.8 | 19.8 | 22.1 | 6.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | (22.1) | (5.8) | (0.0) | (0.0) |
| Asset Writedown | — | 0.3 | 5.3 | 0.0 | 0.0 | — | — |
| EBT, Incl. Unusual Items | (166.8) | (151.2) | (163.9) | (129.5) | (147.2) | (55.1) | (27.0) |
| Income Tax Expense | — | 0.4 | (0.6) | 6.0 | 0.9 | 0.0 | (0.2) |
| Net Income | |||||||
| Net Income | (84.2) | (69.0) | (61.2) | (35.5) | (148.1) | (55.1) | (26.7) |
| Per Share | |||||||
| Basic EPS | — | — | — | — | (0.23) | — | — |
| Diluted EPS | — | — | — | — | (0.23) | — | — |
| Basic Weighted Avg Shares | — | — | — | — | 61.5 | — | — |
| Diluted Weighted Avg Shares | — | — | — | — | 61.5 | — | — |
| Supplemental | |||||||
| EBITDA | — | (158.4) | (178.2) | (147.7) | (150.0) | (53.1) | (26.1) |
| EBIT | (177.2) | (165.0) | (183.7) | (151.5) | (153.0) | (55.1) | (27.0) |
| Effective Tax Rate | — | — | — | -4.6% | -0.6% | -0.1% | 0.9% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.